AstraZeneca (LON:AZN) Given New £150 Price Target at Berenberg Bank

AstraZeneca (LON:AZN) had its price target dropped by analysts at Berenberg Bank from £160 to £150 in a report issued on Tuesday, London Stock Exchange reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Berenberg Bank’s price objective indicates a potential upside of 24.23% from the company’s current price.

A number of other research firms have also weighed in on AZN. Deutsche Bank Aktiengesellschaft reissued a “sell” rating and set a £115 target price on shares of AstraZeneca in a report on Wednesday, September 2nd. Jefferies Financial Group reaffirmed a “buy” rating and set a £175 price objective on shares of AstraZeneca in a research report on Wednesday, September 9th. Citigroup upped their price objective on shares of AstraZeneca from £175 to £178 and gave the company a “buy” rating in a report on Tuesday, July 28th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a £145 price objective on shares of AstraZeneca in a research report on Tuesday, September 8th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of £149.71.

AstraZeneca Price Performance

LON:AZN opened at £120.74 on Tuesday. AstraZeneca has a 12-month low of £107.84 and a 12-month high of £157.32. The firm has a market capitalization of £187.26 billion, a price-to-earnings ratio of 18.07, a P/E/G ratio of 0.86 and a beta of 0.20. The stock’s 50 day moving average price is £122.84 and its two-hundred day moving average price is £135.11. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.